Identifying Broad-Spectrum Influenza Virus Inhibitors

鉴定广谱流感病毒抑制剂

• 批准号: 6832579
• 负责人: Fang Fang
• 金额: $ 44.99万
• 依托单位: NEXBIO, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-01 至 2006-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6832579
• 关键词: MDCK cell; Orthomyxoviridae; SDS polyacrylamide gel electrophoresis; antiviral agents; chick embryo; cysteine endopeptidases; disease /disorder prevention /control; disease outbreaks; drug discovery /isolation; drug quality /standard; drug screening /evaluation; electroporation; enzyme linked immunosorbent assay; hemagglutination test; immunoprecipitation; influenza; peptide library; pharmacokinetics; polymerase chain reaction; protease inhibitor; serine proteinases; subtilisins; tissue /cell culture; trypsin inhibitors

DESCRIPTION (provided by applicant): Broad-spectrum therapeutics for influenza is critically needed to address the problem of influenza pandemics, a major threat to the public health globally. We have proposed studies aiming at identifying molecules that are capable of blocking infections of all strains of influenza viruses by targeting the host factors which are essential for activation of all influenza viruses. In this proposed phase I study, we will generate the drug candidates, charactering and compare their biochemical and functional activities in vitro. Our goal is to have two final candidates identified and ready for further preclinical evaluation in phase II study.

描述（由申请人提供）：急需流感的广谱治疗药物来解决流感大流行问题，这是全球公共卫生的主要威胁。我们已经提出了旨在鉴定能够通过靶向激活所有流感病毒所必需的宿主因子来阻断所有流感病毒株感染的分子的研究。在这项拟议的I期研究中，我们将产生候选药物，表征并比较它们的体外生化和功能活性。我们的目标是确定两种最终候选药物，并准备在II期研究中进行进一步的临床前评价。